Table 1. Baseline characteristics of patients with metastatic colorectal cancer in two groups.
Characteristic | mIFL group (n = 64) | Bevacizumab plus mIFL group (n = 139) |
Sexa | ||
Men | 36 (56.2) | 70 (50.4) |
Women | 28 (44.8) | 69 (49.6) |
Age (years)b | 50 (22–72) | 53 (23–77) |
ECOG performance statusa | ||
0 | 23 (35.9) | 66 (47.5) |
1 | 41 (64.1) | 73 (52.5) |
Primary tumor sitea | ||
Colon | 31 (48.4) | 66 (47.5) |
Rectum | 32 (50.0) | 66 (47.5) |
Colorectum | 1 (1.6) | 7 (5.0) |
Number of metastatic sitesa | ||
1 | 23 (35.9) | 58 (41.7) |
>1 | 41 (64.1) | 81 (58.3) |
Previous cancer therapya | ||
Adjuvant chemotherapy | 25 (39.1) | 70 (50.4) |
Radiotherapy | 12 (18.8) | 17 (12.2) |
ECOG, Eastern Cooperative Oncology Group; mIFL, modified irinotecan, leucovorin bolus, and 5-fluorouracil intravenous infusion. aThe values are presented as number of patients, with the percentage in parentheses. bThe values are median age, with range in the parentheses.